Diabetes Mellitus, Type 1ACT-ONENCT05429359
cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances
A study testing CPET: CardioPulmonary Exercise Test for CSII users, AEX1: Aerobic Exercise Test 1 for CSII users and AEX2: Aerobic Exercise Test 2 for CSII users in people with Diabetes Mellitus, Type 1, run by University Hospital, Antwerp.
Trial summary
Collection of venous blood samples in 50 persons with type 1 diabetes to evaluate the behavior of different biomarkers (glucose, lactate, beta-hydroxybutyrate), and hormones (cortisol, growth hormone) during and after one morning CardioPulmonary Exercise Test and 2 aerobic (90 minutes at 40-45% of VO2 max) exercise… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Diabetes Mellitus, Type 1
- What is being tested?
- CPET: CardioPulmonary Exercise Test for CSII users, AEX1: Aerobic Exercise Test 1 for CSII users and AEX2: Aerobic Exercise Test 2 for CSII users
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2022to 31 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Duration of type 1 diabetes mellitus >5y
- Subjects willing to sign an informed consent form (ICF)
- Age 18-60y
- Using a continuous glucose monitoring system (preferably Guardian or Dexcom for CSII / Freestyle Libre for MDI)
- For CSII: only hybrid closed loop pumps (HCL)
- For MDI: only Tresiba (degludec) \& Toujeo (glargine)
Show all 10Show fewer
- HbA1c 6-8.0% (blood result up to 3 months old)
- BMI 20-27.5 kg/m2
- The participant should be in the categories 'moderately' to 'highly physically active' according to the IPAQ score
- The Physical Activity Coefficient has not changed (from category1) in the 2 months prior to the first Exercise Test
Who cannot join
- Being pregnant or having an active pregnancy wish
- Subject not on MDI or CSII
- Musculoskeletal disorder that affects cycling or is a contra-indication for vigorous physical activity
- Cardiorespiratory disease or ECG abnormality that is a contra-indication for vigorous physical activity
- Having an acute illness (e.g. influenza) that interferes with glucose metabolism
- Having a metabolic disorder (different from diabetes) known to have significant interference with glucose metabolism
Show all 9Show fewer
- Current treatment with drugs known to have significant interference with glucose metabolism, such as systemic corticoids as judged by the investigator
- Presence of concomitant pathology such as heart failure, liver failure, kidney failure (defined as eGFR <45mL/min, blood result up to 12 months old)
- (Severe) food allergies as judged by the investigator
Trial locations and contacts
No sites are listed yet.
About this study
Official title: cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances (ACT-ONE)
Collection of venous blood samples in 50 persons with type 1 diabetes to evaluate the behavior of different biomarkers (glucose, lactate, beta-hydroxybutyrate), and hormones (cortisol, growth hormone) during and after one morning CardioPulmonary Exercise Test and 2 aerobic (90 minutes at 40-45% of VO2 max) exercise tests under different circumstances (see Protocol).
Read the detailed description
This study is an extension of the Action-1 pilot study. This study is an extension of the Action-1 pilot study. The aim is to collect samples of multiple biomarkers (circulating glucose, ketones and lactate levels) and hormones (cortisol and growth hormone) during and following an anaerobic and two aerobic exercise in patients with T1D, under more and well-defined circumstances (bolus insulin reduction in combination with major vs. minor basal insulin reduction) to aim for safer glucose levels during and after exercise (~90-180 mg/dL or ~5-10 mmol/L) and avoid extreme glucose excursions to hypo (< 70 mg/dL or <3.9 mmol/L) or hyperglycemia (>180 mg/dL or >10 mmol/L). Based on these data, we aim to formulate exercise guidelines to better help prevent hypoglycemia during and after exercise. Overall, our goal is to help maintain target glycemic values during and after exercise, as evidenced by >70% time in range (70-180mg/dL) while using Continuous Glucose Monitoring (CGM).
Primary endpoint:
- CGM outcomes during and after morning exercise, determined as:
- Time in range (TIR) 70-180mg/dL
- Time below range (TBR) Level 2, <54 mg/dL
- Time below range (TBR) Level 1 and 2, <70 mg/dL
- Time above range (TAR) Level 1 and 2, >180 mg/dL
- Time above range (TAR) Level 2, >250 mg/dL
Secondary endpoints:
- Evaluate values and trends of glucose, lactate and beta-hydroxybutyrate before, during and after morning exercise in venous blood.
- Evaluate trends of cortisol and growth hormone before, during and after exercise in relationship to possible hypoglycemic (<70mg/dL glucose) and hyperglycemic events (>180mg/dL).
One CardioPulmonary Exercise Test (CPET, symptom limited maximal exercise test) and two Aerobic Exercise Tests at 40-45% VO2max (AEX), with venous blood samples (catheter), heart rate monitoring during the exercise and follow-up to 6h after the exercise.
(The individual VO2max, using a CardioPulmonary Exercise Test, can be determined during the first "Symptom Limited Maximal" Exercise Test. This to assess the VT1 (V-slope relation VCO2 and VO2; Eq02), VT2 (Relation VE and VCO2; EqCO2) and VO2 peak.)
Before exercise Test 1, the CPET, the study participants will receive 7 questions on the physical activity over the last 7 days (IPAQ questionnaire).
The 3 Exercise Tests will be carried out with 2-4 weeks intervals:
- The day before an exercise test and right before, no exercise (only ADL) is allowed (patients should not come to the study center by bike)
- The night before the exercise test, no hypoglycemia must occur, as defined by 15 consecutive minutes, or more, of an interstitial glucose <70 mg/dL
- Target glucose level in the morning: 90-180 mg/dL
- The morning of the exercise test: patients will receive a standardized breakfast (slices of bread with protein spread (containing ±5-25g of protein in total) of in total 0.5g carbohydrates per kg body weight)
- Breakfast at 30 minutes before the exercise with a bolus at the start of the breakfast (100% bolus for CPET, 50% bolus for AEX)
- Pump settings: basal insulin reduction through temporary target of 150 mg/dL during AEX1 and AEX2 will be adjusted 60-120 minutes prior to the start of the exercise and will last until 60 minutes after the exercise (210-270 min in total)
- Lunch (slices of bread with protein spread (containing ±5-25g of protein in total) of in total 0.5g carbohydrates per kg body weight) will be served after 2h of follow-up with a 75% insulin bolus and a correction bolus, if necessary, of 50% of the patient's usual insulin correction dose for the level of hyperglycemia observed.
- Hyperglycemia (>250mg/dL) before, during and after exercise will be corrected according to the patient's treatment schedule at 50% of the patient's usual correction factor.
- Glucose levels below the target glucose of 90 mg/dL during exercise will be corrected with fast-acting carbohydrates: 15g of oral glucose (sports beverage Aquarius Red Peach (7.4g CHO/100ml)), as repeated every 15 minutes, if necessary, until interstitial and/or whole blood glucose is > 70 mg/dL.
CPET:
- Baseline
- VO2peak measurement
- Breakfast
- 100% bolus insulin
- CSII: 100% basal
- MDI: 100% basal
AEX1:
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- CSII: -2h target 150 mg/dL
- MDI: 50% basal
AEX2:
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- CSII: -1h target 150 mg/dL
- MDI: 80% basal
CPET = CardioPulmonary Exercise Test; AEX = Aerobic Exercise Test; CSII = Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps); MDI = Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)
- Conditions
- Diabetes Mellitus, Type 1
- Being tested
- CPET: CardioPulmonary Exercise Test for CSII users, AEX1: Aerobic Exercise Test 1 for CSII users, AEX2: Aerobic Exercise Test 2 for CSII users, CPET: CardioPulmonary Exercise Test for MDI users, AEX1: Aerobic Exercise Test 1 for MDI users
- Keywords
- exercise, biomarker, glucose, lactate, ketones, continuous glucose monitoring, hormones
- Medical subject headings
- Diabetes Mellitus, Type 1, Motor Activity, Ketosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CPET: CardioPulmonary Exercise Test for CSII usersOther
- Baseline
- VO2peak measurement
- Breakfast
- 100% bolus insulin
- CSII users: 100% basal
AEX1: Aerobic Exercise Test 1 for CSII usersOther
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- CSII users: -2h target 150 mg/dL
AEX2: Aerobic Exercise Test 2 for CSII usersOther
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- CSII users: -1h target 150 mg/dL
CPET: CardioPulmonary Exercise Test for MDI usersOther
- Baseline
- VO2peak measurement
- Breakfast
- 100% bolus insulin
- MDI users: 100% basal
AEX1: Aerobic Exercise Test 1 for MDI usersOther
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- MDI users: 50% basal
AEX2: Aerobic Exercise Test 2 for MDI usersOther
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- MDI users: 80% basal
| Study group | Role | What they receive |
|---|---|---|
| CSII users | Active comparator | Patients using Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps) Receives: Other: CPET: CardioPulmonary Exercise Test for CSII users; Other: AEX1: Aerobic Exercise Test 1 for CSII users; Other: AEX2: Aerobic Exercise Test 2 for CSII users |
| MDI users | Active comparator | Patients using Multiple Daily Injections (only Tresiba and Toujeo as basal insulin) Receives: Other: CPET: CardioPulmonary Exercise Test for MDI users; Other: AEX1: Aerobic Exercise Test 1 for MDI users; Other: AEX2: Aerobic Exercise Test 2 for MDI users |
What is being measured
The primary outcome is the main question the study is designed to answer.
CGM outcomes during and after morning exercise
CGM outcomes, determined as:
- Time in range (TIR) 70-180mg/dL
- Time below range (TBR) Level 2, <54 mg/dL
- Time below range (TBR) Level 1 and 2, <70 mg/dL
- Time above range (TAR) Level 1 and 2, >180 mg/dL
- Time above range (TAR) Level 2, >250 mg/dL
Measured: CGM values will be collected up to 8 hours prior to the exercise test and 24 hours after the exercise test
Secondary outcomes (5)
Change in glucose concentration in venous blood during and after morning exercise test
Glucose levels in mg/dL during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET \& AEX1-2), measured through EKF
Measured: Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in lactate concentration in venous blood during and after morning exercise test
Lactate levels in mM during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET \& AEX1-2), measured through EKF
Measured: Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in ketone concentration in venous blood during and after morning exercise test
Ketone (Beta-hydroxybutyrate) levels in mM during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET \& AEX1-2), measured through EKF
Measured: Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in cortisol concentration in venous blood during and after morning exercise test
Cortisol levels during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET \& AEX1-2), measured through venous blood sampling analysis
Measured: Blood sampling was done before the exercise, every 15-30 minutes during the exercise and every 15-30 minutes during the first hour of recovery and every 60-120 minutes during the rest of the 6-hour follow-up
Change in growth hormone concentration in venous blood during and after morning exercise test
Growth hormone levels during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET \& AEX1-2), measured through venous blood sampling analysis
Measured: Blood sampling was done before the exercise, every 15-30 minutes during the exercise and every 15-30 minutes during the first hour of recovery and every 60-120 minutes during the rest of the 6-hour follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2022
- Study start1 Oct 2022 (estimated)
- Primary completion31 Aug 2023 (estimated)
- Study completion31 Mar 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 1Studies of the same condition, open and under way.
- More trials run by University Hospital, AntwerpThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Antwerp
- Sponsor type
- University, hospital or other
- Collaborators
- Universiteit Antwerpen, York University
- Responsible party
- Sponsor
- Investigators
- Christophe De Block, MD, PhD, Principal investigator, University Hospital, Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05429359
- Sponsor's protocol ID
- ACT-ONE
- Acronym
- ACT-ONE
- Status last verified
- Jun 2022
- First submitted
- 17 Jun 2022
- Last updated
- 6 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances (ACT-ONE)
- ClinicalTrials.gov ID
- NCT05429359
- Acronym / sponsor ID
- ACT-ONE / ACT-ONE
- Conditions
- Diabetes Mellitus, Type 1
- Keywords
- exercise, biomarker, glucose, lactate, ketones, continuous glucose monitoring, hormones
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University Hospital, AntwerpUniversity, hospital or other
- Collaborators
- Universiteit Antwerpen, York University
- Study start
- 1 Oct 2022 (estimated)
- Primary completion
- 31 Aug 2023 (estimated)
- Study completion
- 31 Mar 2024 (estimated)
- First posted
- 23 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Collection of venous blood samples in 50 persons with type 1 diabetes to evaluate the behavior of different biomarkers (glucose, lactate, beta-hydroxybutyrate), and hormones (cortisol, growth hormone) during and after one morning CardioPulmonary Exercise Test and 2 aerobic (90 minutes at 40-45% of VO2 max) exercise tests under different circumstances (see Protocol).
Detailed description
This study is an extension of the Action-1 pilot study. This study is an extension of the Action-1 pilot study. The aim is to collect samples of multiple biomarkers (circulating glucose, ketones and lactate levels) and hormones (cortisol and growth hormone) during and following an anaerobic and two aerobic exercise in patients with T1D, under more and well-defined circumstances (bolus insulin reduction in combination with major vs. minor basal insulin reduction) to aim for safer glucose levels during and after exercise (~90-180 mg/dL or ~5-10 mmol/L) and avoid extreme glucose excursions to hypo (< 70 mg/dL or <3.9 mmol/L) or hyperglycemia (>180 mg/dL or >10 mmol/L). Based on these data, we aim to formulate exercise guidelines to better help prevent hypoglycemia during and after exercise. Overall, our goal is to help maintain target glycemic values during and after exercise, as evidenced by >70% time in range (70-180mg/dL) while using Continuous Glucose Monitoring (CGM).
Primary endpoint:
- CGM outcomes during and after morning exercise, determined as:
- Time in range (TIR) 70-180mg/dL
- Time below range (TBR) Level 2, <54 mg/dL
- Time below range (TBR) Level 1 and 2, <70 mg/dL
- Time above range (TAR) Level 1 and 2, >180 mg/dL
- Time above range (TAR) Level 2, >250 mg/dL
Secondary endpoints:
- Evaluate values and trends of glucose, lactate and beta-hydroxybutyrate before, during and after morning exercise in venous blood.
- Evaluate trends of cortisol and growth hormone before, during and after exercise in relationship to possible hypoglycemic (<70mg/dL glucose) and hyperglycemic events (>180mg/dL).
One CardioPulmonary Exercise Test (CPET, symptom limited maximal exercise test) and two Aerobic Exercise Tests at 40-45% VO2max (AEX), with venous blood samples (catheter), heart rate monitoring during the exercise and follow-up to 6h after the exercise.
(The individual VO2max, using a CardioPulmonary Exercise Test, can be determined during the first "Symptom Limited Maximal" Exercise Test. This to assess the VT1 (V-slope relation VCO2 and VO2; Eq02), VT2 (Relation VE and VCO2; EqCO2) and VO2 peak.)
Before exercise Test 1, the CPET, the study participants will receive 7 questions on the physical activity over the last 7 days (IPAQ questionnaire).
The 3 Exercise Tests will be carried out with 2-4 weeks intervals:
- The day before an exercise test and right before, no exercise (only ADL) is allowed (patients should not come to the study center by bike)
- The night before the exercise test, no hypoglycemia must occur, as defined by 15 consecutive minutes, or more, of an interstitial glucose <70 mg/dL
- Target glucose level in the morning: 90-180 mg/dL
- The morning of the exercise test: patients will receive a standardized breakfast (slices of bread with protein spread (containing ±5-25g of protein in total) of in total 0.5g carbohydrates per kg body weight)
- Breakfast at 30 minutes before the exercise with a bolus at the start of the breakfast (100% bolus for CPET, 50% bolus for AEX)
- Pump settings: basal insulin reduction through temporary target of 150 mg/dL during AEX1 and AEX2 will be adjusted 60-120 minutes prior to the start of the exercise and will last until 60 minutes after the exercise (210-270 min in total)
- Lunch (slices of bread with protein spread (containing ±5-25g of protein in total) of in total 0.5g carbohydrates per kg body weight) will be served after 2h of follow-up with a 75% insulin bolus and a correction bolus, if necessary, of 50% of the patient's usual insulin correction dose for the level of hyperglycemia observed.
- Hyperglycemia (>250mg/dL) before, during and after exercise will be corrected according to the patient's treatment schedule at 50% of the patient's usual correction factor.
- Glucose levels below the target glucose of 90 mg/dL during exercise will be corrected with fast-acting carbohydrates: 15g of oral glucose (sports beverage Aquarius Red Peach (7.4g CHO/100ml)), as repeated every 15 minutes, if necessary, until interstitial and/or whole blood glucose is > 70 mg/dL.
CPET:
- Baseline
- VO2peak measurement
- Breakfast
- 100% bolus insulin
- CSII: 100% basal
- MDI: 100% basal
AEX1:
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- CSII: -2h target 150 mg/dL
- MDI: 50% basal
AEX2:
- 90min
- 40-45% VO2peak
- Breakfast
- 50% bolus insulin
- CSII: -1h target 150 mg/dL
- MDI: 80% basal
CPET = CardioPulmonary Exercise Test; AEX = Aerobic Exercise Test; CSII = Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps); MDI = Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CSII users | Active comparator | Other: CPET: CardioPulmonary Exercise Test for CSII users, Other: AEX1: Aerobic Exercise Test 1 for CSII users, Other: AEX2: Aerobic Exercise Test 2 for CSII usersPatients using Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps) |
| MDI users | Active comparator | Other: CPET: CardioPulmonary Exercise Test for MDI users, Other: AEX1: Aerobic Exercise Test 1 for MDI users, Other: AEX2: Aerobic Exercise Test 2 for MDI usersPatients using Multiple Daily Injections (only Tresiba and Toujeo as basal insulin) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Duration of type 1 diabetes mellitus >5y
- Subjects willing to sign an informed consent form (ICF)
- Age 18-60y
- Using a continuous glucose monitoring system (preferably Guardian or Dexcom for CSII / Freestyle Libre for MDI)
- For CSII: only hybrid closed loop pumps (HCL)
Key exclusion criteria (9 listed)
- Being pregnant or having an active pregnancy wish
- Subject not on MDI or CSII
- Musculoskeletal disorder that affects cycling or is a contra-indication for vigorous physical activity
- Cardiorespiratory disease or ECG abnormality that is a contra-indication for vigorous physical activity
- Having an acute illness (e.g. influenza) that interferes with glucose metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CPET: CardioPulmonary Exercise Test for CSII users* Baseline * VO2peak measurement * Breakfast * 100% bolus insulin * CSII users: 100% basal | Other | CSII users |
| AEX1: Aerobic Exercise Test 1 for CSII users* 90min * 40-45% VO2peak * Breakfast * 50% bolus insulin * CSII users: -2h target 150 mg/dL | Other | CSII users |
| AEX2: Aerobic Exercise Test 2 for CSII users* 90min * 40-45% VO2peak * Breakfast * 50% bolus insulin * CSII users: -1h target 150 mg/dL | Other | CSII users |
| CPET: CardioPulmonary Exercise Test for MDI users* Baseline * VO2peak measurement * Breakfast * 100% bolus insulin * MDI users: 100% basal | Other | MDI users |
| AEX1: Aerobic Exercise Test 1 for MDI users* 90min * 40-45% VO2peak * Breakfast * 50% bolus insulin * MDI users: 50% basal | Other | MDI users |
| AEX2: Aerobic Exercise Test 2 for MDI users* 90min * 40-45% VO2peak * Breakfast * 50% bolus insulin * MDI users: 80% basal | Other | MDI users |
Primary outcome
CGM outcomes during and after morning exercise
Time frame: CGM values will be collected up to 8 hours prior to the exercise test and 24 hours after the exercise test
CGM outcomes, determined as: * Time in range (TIR) 70-180mg/dL * Time below range (TBR) Level 2, <54 mg/dL * Time below range (TBR) Level 1 and 2, <70 mg/dL * Time above range (TAR) Level 1 and 2, >180 mg/dL * Time above range (TAR) Level 2, >250 mg/dL
5 secondary outcomes
Change in glucose concentration in venous blood during and after morning exercise test
Time frame: Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in lactate concentration in venous blood during and after morning exercise test
Time frame: Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in ketone concentration in venous blood during and after morning exercise test
Time frame: Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in cortisol concentration in venous blood during and after morning exercise test
Time frame: Blood sampling was done before the exercise, every 15-30 minutes during the exercise and every 15-30 minutes during the first hour of recovery and every 60-120 minutes during the rest of the 6-hour follow-up
Change in growth hormone concentration in venous blood during and after morning exercise test
Time frame: Blood sampling was done before the exercise, every 15-30 minutes during the exercise and every 15-30 minutes during the first hour of recovery and every 60-120 minutes during the rest of the 6-hour follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Sep 2022.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus, Type 1
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christophe De Block, MD, PhD principal investigator
University Hospital, Antwerp
Questions about this trial
What is this clinical trial studying?
A study testing CPET: CardioPulmonary Exercise Test for CSII users, AEX1: Aerobic Exercise Test 1 for CSII users and AEX2: Aerobic Exercise Test 2 for CSII users in people with Diabetes Mellitus, Type 1, run by University Hospital, Antwerp.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christophe De Block, MD, PhD (+3238214364, christophe.deblock@uza.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CGM outcomes during and after morning exercise (time frame: CGM values will be collected up to 8 hours prior to the exercise test and 24 hours after the exercise test). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Sep 2022.